Liverpool-ECMC

From: Sent: To: Subject:

Follow Up Flag: Flag Status: Liverpool-ECMC 05 December 2019 09:26 Liverpool-ECMC Liverpool ECMC Newsletter December 2019 - Haematology

Follow up Completed

LIVERPOOL ECMC NEWSLETTER DECEMBER 2019 HAEMATOLOGY



UK-EDI LAUNCH

A new CR-UK funded programme, the UK Early Detection Initiative for Pancreatic Cancer (UK-EDI), was launched in Liverpool on the 20th November, the eve of World Pancreatic Cancer Day.

The programme aims to investigate the link between the development of new onset diabetes in patients diagnosed with pancreatic cancer in order to develop a test to detect pancreatic cancer earlier.


The programme is led by Professor Eithne Costello from the University of Liverpool and is looking to recruit 2500 participants aged 50 or over who have recently developed new onset diabetes. UK-EDI is supported by the Liverpool ECMC.

For further information on the programme please contact the study team at **ukedi@liv.ac.uk**.

PSGBI ANNUAL MEETING



<u>The Pancreatic Society of Great Britain and Ireland (PSGBI)</u> chose to hold its annual meeting in Liverpool on the 21st and 22nd of November, coinciding with World Pancreas Day and the University lit up the engineering building in purple to mark the occasion.



Leading pancreatologists from across Europe gathered for the meeting, which was held in the Metropolitan Cathedral and featured presentations from ECMC researchers from Liverpool and elsewhere, including the President of the Society, Prof. Bill Greenhalf, who is also the scientific lead for our ECMC.

OPEN TRIALS

Please contact <u>Jane Tinsley</u> for potential referral to these trials.



• Telephone: 0151 706 4886

• **<u>AVAIL-T</u>** – A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)

• <u>HARMONY</u> – A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

• <u>HERACLES</u> – Treatment of steroid refractory gastro-intestinal acute graftversus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with faEcal microbiota transfer

• <u>TIDaL</u> – Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

Find out more...

EVENTS & JOB OPPORTUNITIES

EVENTS

• <u>ECMC Junior Investigator Network Group: Training the Next</u> <u>Generation (FEBRUARY 2020)</u>

https://www.ecmcnetwork.org.uk/events

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via <u>e-mail</u>.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is: livecmc@liv.ac.uk